Evidence map›Paper›PMID 37534455›Full record

ArticleThe Journal of international medical research2023

Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report.

Jia Cong, HyonSu Jo, Na Zou, LingXin Kong, HyokJu Ri

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Jia CongDepartment of Breast Surgery, Dalian Women and Children's Medical Group, Dalian, People's Republic of China.
HyonSu JoDepartment of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Na ZouDepartment of Pathology, Dalian Women and Children's Medical Group, Dalian, People's Republic of China.
LingXin KongDepartment of Radiology, Dalian Women and Children's Medical Group, Dalian, People's Republic of China.
HyokJu RiDepartment of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.ORCID 0000-0002-5172-7029
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.

Indexed as

Breast NeoplasmsCarcinoma, Squamous CellAntineoplastic Combined Chemotherapy ProtocolsEpithelial CellsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyTreatment OutcomeErb-b2 Receptor Tyrosine KinasesAcantholytic squamous cell carcinomabreast cancerbreast surgeryHER2-positiveimmunohistochemistryneoadjuvant therapy

Identifiers

PMID37534455
PMCPMC10566270
OpenAlexW4385513885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.